GlassScriptPhysician profile
Matthew Michael Grove
NPI 1841322260
$5,770.11
in general payments reported to CMS, 2019-2025
43 companies · $759 in 2025
The $759 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $388 · 2021: $962 · 2022: $1,080 · 2023: $1,224 · 2024: $960 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,930 · Education: $13.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,930.25 |
| Education | $13.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $821.61 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $814.28 | 2020-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $686.37 | 2020-2025 | Opsumit, Uptravi, Opsynvi |
| Abbott Laboratories | $338.93 | 2019-2023 | Amplatzer Amulet, Mitraclip |
| Merck Sharp & Dohme LLC | $295.87 | 2021-2025 | Verquvo, Winrevair |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $277.41 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $222.73 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $214.41 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $192.01 | 2019-2025 | Brilinta |
| Amgen INC. | $181.05 | 2020-2025 | Repatha |
| Pfizer INC. | $163.06 | 2022-2025 | |
| Novo Nordisk INC | $151.75 | 2021-2025 | Wegovy, Ozempic |
| Esperion Therapeutics, INC. | $133.27 | 2020-2023 | Nexletol |
| Amarin Pharma, INC. | $119.21 | 2020-2022 | |
| United Therapeutics Corporation | $117.52 | 2022-2025 | Tyvaso, Tyvaso, Orenitram |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Grove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.